What type of study is this?

September 10, 2025Journal of Clinical Research and Reports0 citations

Alectinib-Related Hepatic Toxicity in A patient with Advanced ALK-Positive Non-Small-Cell Lung Cancer

Key Points

Hepatic toxicity was observed during Alectinib treatment for ALK-positive NSCLC, indicating significant adverse effects.
The patient developed cognitive impairment alongside hepatic toxicity, showing the complexity of Alectinib-related adverse events.
Detailed analysis revealed the patient's progression to stage IV ALK-positive NSCLC, emphasizing the severity of the condition.
This case underscores the need for careful monitoring of hepatic function in patients receiving Alectinib therapy.

Abstract

Alectinib is suggested as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Nevertheless, despite being generally well-tolerated, drug-related adverse events (AEs) like hepatotoxicity and cognitive impairment are still not fully understood. We report the case of a patient affected by stage IV ALK-positive NSCLC who developed hepatic toxicity and cognitive decline during Alectinib treatment.

问 AI

Bookmark

View Full Paper

Cite This Study

Beatrice Ruffilli (Mon,) studied this question.

synapsesocial.com/papers/68c1a8fe54b1d3bfb60e1c02 https://doi.org/https://doi.org/10.31579/2690-1919/536

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

问 AI

Bookmark

View Full Paper